end,filed,form,Name,Ticker,CIK,Currency,AccountsPayableCurrent,AccruedEmployeeBenefitsCurrent,AccruedLiabilitiesCurrent,AccruedLiabilitiesCurrentAndNoncurrent,AccruedProfessionalFeesCurrentAndNoncurrent,AdditionalPaidInCapitalCommonStock,AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue,AllocatedShareBasedCompensationExpense,AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount,Assets,AssetsCurrent,CashAndCashEquivalentsAtCarryingValue,CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents,CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect,CommonStockParOrStatedValuePerShare,CommonStockSharesAuthorized,CommonStockSharesIssued,CommonStockSharesOutstanding,CommonStockValue,ConvertiblePreferredStockNonredeemableOrRedeemableIssuerOptionValue,ConvertiblePreferredStockSharesIssuedUponConversion,CostsAndExpensesRelatedParty,EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized,IncomeLossFromContinuingOperationsPerBasicAndDilutedShare,IncomeTaxExpenseBenefit,IncreaseDecreaseInAccountsPayable,IncreaseDecreaseInAccruedLiabilities,IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets,InvestmentIncomeInterest,Liabilities,LiabilitiesAndStockholdersEquity,LiabilitiesCurrent,NetCashProvidedByUsedInFinancingActivities,NetCashProvidedByUsedInOperatingActivities,NetIncomeLoss,NonoperatingIncomeExpense,OperatingExpenses,OperatingIncomeLoss,OtherAccruedLiabilitiesCurrentAndNoncurrent,OtherAssetsCurrent,OtherNonoperatingGainsLosses,PreferredStockLiquidationPreferenceValue,PreferredStockSharesAuthorized,PreferredStockSharesIssued,PreferredStockSharesOutstanding,PreferredStockValue,PrepaidExpenseAndOtherAssetsCurrent,ProceedsFromIssuanceOfConvertiblePreferredStock,ProfitLoss,ResearchAndDevelopmentExpense,RetainedEarningsAccumulatedDeficit,RoyaltyExpense,SaleOfStockPricePerShare,SellingGeneralAndAdministrativeExpense,ShareBasedCompensation,ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod,ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber,ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod,ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber,ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice,ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod,ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross,ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue,ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue,ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber,ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice,ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue,ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber,ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice,ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice,ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice,ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice,SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1,StockholdersEquity,StockIssuedDuringPeriodSharesStockOptionsExercised,StockIssuedDuringPeriodValueNewIssues,StockIssuedDuringPeriodValueStockOptionsExercised,TreasuryStockShares,TreasuryStockValue,WeightedAverageNumberOfShareOutstandingBasicAndDiluted,AccretionAmortizationOfDiscountsAndPremiumsInvestments,AccumulatedOtherComprehensiveIncomeLossNetOfTax,AdjustmentForAmortization,AssetsFairValueAdjustment,AvailableForSaleSecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue,CommonStockCapitalSharesReservedForFutureIssuance,ComprehensiveIncomeNetOfTax,GainLossOnInvestmentsExcludingOtherThanTemporaryImpairments,IncreaseDecreaseInOtherNoncurrentAssets,InterestReceivable,MarketableSecurities,NetCashProvidedByUsedInInvestingActivities,OperatingLeasesRentExpenseNet,OtherAssetsNoncurrent,OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent,PaymentsToAcquireMarketableSecurities,PreferredStockParOrStatedValuePerShare,PrepaidInsurance,ProceedsFromIssuanceOfCommonStock,ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock,ProceedsFromStockOptionsExercised,RealizedGainLossOnMarketableSecuritiesCostMethodInvestmentsAndOtherInvestments,ResearchAndDevelopmentInProcess,SaleLeasebackTransactionMonthlyRentalPayments,StockIssuedDuringPeriodValueConversionOfConvertibleSecurities,StockRepurchasedDuringPeriodValue,TemporaryEquityLiquidationPreference,TemporaryEquitySharesAuthorized,TemporaryEquitySharesIssued,TemporaryEquitySharesOutstanding,UnrealizedGainOnSecurities,UnrealizedLossOnSecurities
2021-06-30,2021-09-20,10-Q,"Adagio Therapeutics, Inc.",ADGI,CIK0001832038,USD,10716000.0,1272000.0,27181000.0,27181000.0,2262000.0,4067000.0,3342000.0,3342000.0,103848980.0,397992000.0,396059000.0,392509000.0,392509000.0,,0.0001,150000000.0,5599240.0,5599240.0,1000.0,504711000.0,84722420.0,247000.0,69600000.0,-0.18,0.0,,,,23000.0,37905000.0,397992000.0,37897000.0,,,-44673000.0,18000.0,44691000.0,-44691000.0,4000.0,261000.0,-5000.0,505399000.0,16944484.0,16944484.0,16944484.0,504711000.0,3550000.0,,,35067000.0,-148692000.0,,8.0,7124000.0,,,4194930.0,,92500.0,12.8,,,6.75,77563000.0,14931630.0,7.61,77563000.0,14931630.0,7.61,,,,0.0,-144624000.0,,66000.0,3000.0,0.0,0.0,249769.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
2021-09-30,2021-11-15,10-Q,"Adagio Therapeutics, Inc.",ADGI,CIK0001832038,USD,17564000.0,2575000.0,35485000.0,35485000.0,2239000.0,842272000.0,5979000.0,5979000.0,21320100.0,686270000.0,680155000.0,478269000.0,478269000.0,,0.0001,1000000000.0,111251660.0,111251660.0,5000.0,0.0,,1826000.0,86700000.0,-0.98,0.0,,,,48000.0,53057000.0,686270000.0,53049000.0,,,-60375000.0,43000.0,60418000.0,-60418000.0,660000.0,579000.0,-5000.0,,10000000.0,0.0,0.0,0.0,13833000.0,,,45366000.0,-209067000.0,,8.0,11052000.0,,,3859139.0,,1025630.0,2.32,,,9.03,586814000.0,17460961.0,8.63,586814000.0,17460961.0,8.63,,,,40943000.0,633213000.0,,,1000.0,0.0,0.0,61297086.0,,3000.0,,,0.0,36417895.0,-60372000.0,,,682000.0,188053000.0,,100000.0,6115000.0,3000.0,,0.0001,4558000.0,,,,,,,504709000.0,,,,,,,
